Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | +1.43% | +0.71% | +5.97% |
Apr. 24 | Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy | CI |
Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Financials (USD)
Sales 2024 * | 5.59M | Sales 2025 * | 45.44M | Capitalization | 358M |
---|---|---|---|---|---|
Net income 2024 * | -89M | Net income 2025 * | -73M | EV / Sales 2024 * | 20.1 x |
Net cash position 2024 * | 246M | Net cash position 2025 * | 157M | EV / Sales 2025 * | 4.43 x |
P/E ratio 2024 * |
-4.22
x | P/E ratio 2025 * |
-6.21
x | Employees | 202 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.01% |
Latest transcript on Precigen, Inc.
1 day | +1.43% | ||
1 week | +0.71% | ||
Current month | +7.58% | ||
1 month | +1.43% | ||
3 months | +2.90% | ||
6 months | +17.36% | ||
Current year | +5.97% |
Managers | Title | Age | Since |
---|---|---|---|
Helen Sabzevari
CEO | Chief Executive Officer | 62 | 19-12-31 |
Harry Thomasian
DFI | Director of Finance/CFO | 62 | 21-09-30 |
Randal Kirk
CHM | Chairman | 70 | 08-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randal Kirk
CHM | Chairman | 70 | 08-01-31 |
Dean Mitchell
BRD | Director/Board Member | 68 | 09-02-28 |
Jeffrey Perez
PRN | Corporate Officer/Principal | 52 | 14-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 1.42 | +1.43% | 600,018 |
24-05-02 | 1.4 | 0.00% | 753,721 |
24-05-01 | 1.4 | +6.06% | 683,632 |
24-04-30 | 1.32 | -5.71% | 496,540 |
24-04-29 | 1.4 | -0.71% | 381,256 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.97% | 358M | |
+26.08% | 662B | |
+21.73% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 289B | |
+13.68% | 234B | |
+4.54% | 198B | |
-10.76% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- PGEN Stock